Literature DB >> 21820428

The role of innate immunity in the pathogenesis of preneoplasia in drug-induced chronic hepatitis based on a mouse model.

S W French1, F Bardag-Gorce, B A French, J Li, J Oliva.   

Abstract

Innate immunity factors such as conversion of the 26S proteasome to form the immunoproteasome and the Toll-like receptor signaling pathways are activated in chronic hepatitis induced by the carcinogenic drug DDC. Over time, preneoplastic hepatocyte phenotypes appear in the liver parenchyma. These changed hepatocytes expand in number because they have a growth advantage over normal hepatocytes when responding to chronic liver injury. The changed hepatocytes can be identified using immunofluorescent antibodies to preneoplastic cells e.g. FAT10/UbD, A2 macroglobulin, glutathione transpeptidase, alpha fetoprotein, glycipan 3, FAS, and gamma glutamyl transpeptidase. The formation of the preneoplastic cells occurs concomitant with activation of the Toll-like receptor signaling pathways and the transformation of the 26S proteasome to form the immunoproteasome. This transformation is in response to interferon stimulating response element on the promoter of the FAT10/UbD gene. NFκB, Erk, p38 and Jnk are also up regulated. Specific inhibitors block these responses in vitro in a mouse tumor cell line exposed to interferon gamma. Mallory-Denk bodies form in these preneoplastic cells, because of the depletion of the 26S proteasome due to formation of the immunoproteasome. Thus, MDB forming cells are also markers of the preneoplastic hepatocytes. The UbD positive preneoplastic cells regress when the liver injury induced chronic hepatitis subsides. When the drug DDC is refed to mice and chronic hepatitis is activated, the preneoplastic cell population expands and Mallory-Denk bodies rapidly reform. This response is remembered by the preneoplastic cells for at least four months indicating that an epigenetic cellular memory has formed in the preneoplastic cells. This proliferative response is prevented by feeding methyl donors such as S-adenosylmethionine or betaine. Drug feeding reduces the methylation of H(3) K4, 9, and 27 and this response is prevented by feeding the methyl donors. After 8 to 15months of drug withdrawal in mice the preneoplastic liver cells persist as single or small clusters of cells in the liver lobules. Multiple liver tumors form, some of which are hepatocellular carcinomas. The tumors immunostain positively for the same preneoplastic markers as the preneoplastic cells. Similar cells are identified in human cirrhosis and hepatocellular carcinoma indicating the relevance of the drug model described here to the preneoplastic changes associated with human chronic hepatitis and hepatocellular carcinoma.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21820428      PMCID: PMC3482129          DOI: 10.1016/j.yexmp.2011.07.004

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  40 in total

1.  S-adenosylmethionine prevents the up regulation of Toll-like receptor (TLR) signaling caused by chronic ethanol feeding in rats.

Authors:  Joan Oliva; Fawzia Bardag-Gorce; Jun Li; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2011-01-25       Impact factor: 3.362

Review 2.  Histone lysine methylation: an epigenetic modification?

Authors:  Neil P Blackledge; Robert J Klose
Journal:  Epigenomics       Date:  2010-02       Impact factor: 4.778

3.  Mallory body forming cells express the preneoplastic hepatocyte phenotype.

Authors:  Li Nan; Fawzia Bardag-Gorce; Yong Wu; Jun Li; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2006-01-18       Impact factor: 3.362

4.  Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions.

Authors:  Xianzhuo Zeng; Shuai Chen; Haojie Huang
Journal:  Cell Cycle       Date:  2011-02-15       Impact factor: 4.534

Review 5.  Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing.

Authors:  Britta Strehl; Ulrike Seifert; Elke Krüger; Sylvia Heink; Ulrike Kuckelkorn; Peter-M Kloetzel
Journal:  Immunol Rev       Date:  2005-10       Impact factor: 12.988

6.  The role of laminin-integrin signaling in triggering MB formation. An in vivo and in vitro study.

Authors:  Yong Wu; Li Nan; Fawzia Bardag-Gorce; Jun Li; Barbaba A French; La Toyia Wilson; Jennifer Dedes; Samuel W French
Journal:  Exp Mol Pathol       Date:  2005-08       Impact factor: 3.362

7.  The identification of stem cells in human liver diseases and hepatocellular carcinoma.

Authors:  Joan Oliva; Barbara A French; X Qing; Samuel W French
Journal:  Exp Mol Pathol       Date:  2010-01-18       Impact factor: 3.362

8.  TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG.

Authors:  Kurt A Heldwein; Michael D Liang; Tonje K Andresen; Karen E Thomas; Aileen M Marty; Natalia Cuesta; Stefanie N Vogel; Matthew J Fenton
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

Review 9.  Molecular events in hepatic preneoplasia: a review.

Authors:  S W French
Journal:  Exp Mol Pathol       Date:  2010-01-22       Impact factor: 3.362

Review 10.  Innate immune response and hepatic inflammation.

Authors:  Gyongyi Szabo; Pranoti Mandrekar; Angela Dolganiuc
Journal:  Semin Liver Dis       Date:  2007-11       Impact factor: 6.115

View more
  12 in total

1.  Over expression of proteins that alter the intracellular signaling pathways in the cytoplasm of the liver cells forming Mallory-Denk bodies.

Authors:  N Afifiyan; B Tillman; B A French; M Masouminia; S Samadzadeh; S W French
Journal:  Exp Mol Pathol       Date:  2017-01-13       Impact factor: 3.362

2.  Extended lifespan and reduced adiposity in mice lacking the FAT10 gene.

Authors:  Allon Canaan; Jason DeFuria; Eddie Perelman; Vincent Schultz; Montrell Seay; David Tuck; Richard A Flavell; Michael P Snyder; Martin S Obin; Sherman M Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-24       Impact factor: 11.205

3.  Mallory-Denk bodies form when EZH2/H3K27me3 fails to methylate DNA in the nuclei of human and mice liver cells.

Authors:  B A French; J Oliva; F Bardag-Gorce; J Li; J Zhong; V Buslon; S W French
Journal:  Exp Mol Pathol       Date:  2012-03-21       Impact factor: 3.362

4.  TLR3/4 signaling is mediated via the NFκB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.

Authors:  Hui Liu; Jun Li; Brittany Tillman; Timothy R Morgan; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2014-07-02       Impact factor: 3.362

5.  Balloon liver cells forming Mallory-Denk-bodies are progenitor cells.

Authors:  S W French; E Vitocruz; B A French
Journal:  Exp Mol Pathol       Date:  2013-06-14       Impact factor: 3.362

6.  Altered regulation of miR-34a and miR-483-3p in alcoholic hepatitis and DDC fed mice.

Authors:  Hui Liu; Barbara A French; Jun Li; Brittany Tillman; Samuel W French
Journal:  Exp Mol Pathol       Date:  2015-09-25       Impact factor: 3.362

7.  FAT10 knock out mice livers fail to develop Mallory-Denk bodies in the DDC mouse model.

Authors:  S W French; B A French; J Oliva; J Li; F Bardag-Gorce; B Tillman; A Canaan
Journal:  Exp Mol Pathol       Date:  2012-09-12       Impact factor: 3.362

8.  IL-8 signaling is up-regulated in alcoholic hepatitis and DDC fed mice with Mallory Denk Bodies (MDBs) present.

Authors:  Hui Liu; Barbara A French; Tyler J Nelson; Jun Li; Brittany Tillman; Samuel W French
Journal:  Exp Mol Pathol       Date:  2015-08-08       Impact factor: 3.362

Review 9.  Epigenetic events in liver cancer resulting from alcoholic liver disease.

Authors:  Samuel W French
Journal:  Alcohol Res       Date:  2013

Review 10.  Modification by ubiquitin-like proteins: significance in apoptosis and autophagy pathways.

Authors:  Umar-Faruq Cajee; Rodney Hull; Monde Ntwasa
Journal:  Int J Mol Sci       Date:  2012-09-19       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.